ChemoMetec A/S Revenue and Competitors
Estimated Revenue & Valuation
- ChemoMetec A/S's estimated annual revenue is currently $34.7M per year.
- ChemoMetec A/S's estimated revenue per employee is $155,000
Employee Data
- ChemoMetec A/S has 224 Employees.
- ChemoMetec A/S grew their employee count by 5% last year.
ChemoMetec A/S's People
| Name | Title | Email/Phone |
|---|
ChemoMetec A/S Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $81.4M | 375 | 40% | N/A | N/A |
#2 | $16.9M | 109 | 22% | N/A | N/A |
#3 | $156.1M | 120 | -70% | $145M | N/A |
#4 | $2.9M | 37 | -24% | $150M | N/A |
#5 | $1.3M | 17 | 0% | $459.5M | N/A |
#6 | $49.2M | 254 | 15% | $180.7M | N/A |
#7 | $7M | 45 | -2% | N/A | N/A |
#8 | $256.3M | 840 | 9% | $168.5M | N/A |
#9 | $10.1M | 65 | 5% | N/A | N/A |
#10 | $16.1M | 104 | 9% | N/A | N/A |
What Is ChemoMetec A/S?
ChemoMetec is a worldwide leading manufacturer of cell counting and analysis equipment. We specialize in developing and producing high-precision instrumentation, delivering consistent data for thousands of customers across biotech, pharma and academic segments. \n\nWe are experiencing exponential growth, as the company strives towards our goal to be the number one provider in Life Sciences. \n\nDesigned, manufactured and tested in Denmark, our instruments and consumables are built with quality materials and dedicated expert workmanship. \n\nFind us on Glassdoor: https://bit.ly/3pjjzTA
keywords:N/A
N/A
Total Funding
224
Number of Employees
$34.7M
Revenue (est)
5%
Employee Growth %
N/A
Valuation
N/A
Accelerator
ChemoMetec A/S News
... Novartis AG, Enzon Pharmaceuticals, Inc., Bayer AG, Sigma-Aldrich, Abbott Laboratories, Eli Lily and Company, BD, ChemoMetec A/S.
Other Companies in
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $35.7M | 224 | 7% | N/A |
#2 | $56.2M | 224 | 7% | N/A |
#3 | $61.8M | 224 | 8% | N/A |
#4 | $61.8M | 224 | 11% | N/A |
#5 | $50.5M | 224 | 6% | N/A |